3
FDA-Approved Drugs
anastrozole, letrozole, exemestane — all now cheap generics
1
FDA-Approved Use
postmenopausal hormone-receptor+ breast cancer. Every other use below is OFF-LABEL.
OR 1.72
Letrozole Live-Birth Edge
vs the old standard (clomiphene) for PCOS ovulation — Cochrane, 41 trials, high certainty
$0–37
Monthly Cost
generic; letrozole can be ~$0–10/mo. Also WADA-banned for athletes.
An aromatase inhibitor isn't one thing with one verdict. It's a single mechanism — block the enzyme that makes estrogen — pointed at three very different problems. The evidence is rock-solid for two of them and genuinely thin and contested for the third. This chart sets honest expectations before the detail below.
Breast Cancer
Postmenopausal HR+ — FDA-approved, tens of thousands of women in randomized trials. The gold-standard use.
Fertility (Letrozole)
Ovulation for PCOS — off-label but now the GUIDELINE first-line, beating the old drug on live births (high-certainty evidence).
Men: TRT & Fertility
Estrogen control on testosterone + male infertility — off-label, small studies, real risks, genuinely contested.
Your body makes estrogen by converting androgens (like testosterone) using an enzyme called aromatase. These drugs block that enzyme — in postmenopausal women they cut circulating estrogen by up to ~98%. The same single action explains all three uses: starve a cancer of its fuel, or lift the brain's estrogen "brake" so it pumps out more fertility hormones.
Crush Estrogen
−98%
In postmenopausal women, third-generation AIs suppress whole-body estrogen by ~96–98%. That's the point in breast cancer: most postmenopausal breast tumors are fueled by estrogen, so cutting it off starves them.
Raise the T:E2 Ratio
↑ Testosterone
Less testosterone gets converted to estradiol, so testosterone rises and estradiol falls. This is why men use them — but estradiol is NOT a waste product; men need some, and pushing it too low backfires (see Side Effects).
Lift the Brain's "Brake"
Triggers Ovulation
Low estrogen tells the brain to release more FSH — the hormone that grows an egg follicle. That's how letrozole induces ovulation: a few days early in the cycle, then it clears out. Same trick raises FSH/LH in men.
Two Chemical Types
2 Classes
Non-steroidal & reversible: anastrozole (Arimidex), letrozole (Femara) — the two used for fertility. Steroidal & irreversible: exemestane (Aromasin) — permanently disables the enzyme. All three work; they differ in chemistry and side-effect feel.
This is the use the drugs were built for and the only one the FDA has approved: postmenopausal, hormone-receptor-positive breast cancer. Here, AIs are first-line standard of care — better than the older drug tamoxifen at preventing recurrence — backed by trials enrolling tens of thousands of women. The honest trade-off: that benefit comes with more bone loss and fractures (see Side Effects).
| # |
Study |
Type / n |
What It Found |
| 1 |
EBCTCG patient-level meta-analysis — AI vs tamoxifen (premenopausal + ovarian suppression)
|
Meta-analysis
4 trials, n=7,030 |
Fewer recurrences
Recurrence rate ratio 0.79; 5-yr recurrence 6.9% vs 10.1%. But more fractures (RR 1.27). |
| 2 |
Anastrozole vs letrozole vs exemestane head-to-head (postmenopausal, early-stage)
|
Target-trial emulation
n=148,436 |
Anastrozole ≈ Letrozole > Exemestane
8-yr survival 90.5% / 89.9% vs 88.8%; exemestane slightly worse + more discontinuation. |
| 3 |
Anastrozole — the original adjuvant + advanced-disease trials (ATAC and others)
|
Review of RCTs |
Standard of care
Longer disease-free survival + better tolerability than tamoxifen in postmenopausal HR+ disease. |
Here's the surprise: an estrogen-blocking cancer drug is now the first-line fertility medicine for women with PCOS — the most common cause of irregular periods and ovulation problems. Used off-label, taken for just five days early in the cycle, letrozole beats the decades-old standard clomiphene on the outcome that matters most: a live baby. It also helps a specific group of infertile men. This is off-label use the evidence strongly supports.
Women: PCOS Ovulation
+72%
Higher odds of a live birth vs clomiphene (odds ratio 1.72) across 41 trials and 6,522 women — rated high-certainty evidence, with the same low rate of dangerous ovarian over-stimulation.
The Guideline Verdict
First-Line
The 2023 International PCOS Guideline names letrozole the preferred first-line drug for ovulation. In the landmark NIH trial it gave a 27.5% live-birth rate vs 19.1% for clomiphene — with no increased birth-defect risk.
Men: Low T:E2 Infertility
5.5×
In men with poor sperm counts and a low testosterone-to-estradiol ratio, letrozole raised sperm concentration up to 5.5× in a small study; another saw the T:E2 ratio improve ~1,600% and 20% of couples conceive naturally.
The Honest Catch (Men)
Clomiphene Won
A 2024 network meta-analysis of 14 trials found clomiphene improved sperm concentration more than aromatase inhibitors, and concluded there's insufficient evidence to use AIs routinely for male infertility. They help a select subgroup, not everyone.
Women / PCOS
2.5–7.5 mg/day × 5 days
letrozole, cycle days 3–7; dose stepped up if no ovulation ("stair-step")
Men (off-label)
2.5 mg, 2–3×/week
letrozole or anastrozole 1 mg, prescriber-monitored with bloodwork
Important
Taken to conceive, then stopped — never during a known pregnancy
Doses are illustrative, not a prescription. Fertility use is doctor-supervised.
This is the most popular use in the testosterone/bodybuilding world — and the most contested. When men take testosterone, some of it converts to estradiol; a few get high-estrogen symptoms (breast tenderness, water retention). Many clinics reflexively add an AI like anastrozole to every testosterone prescription. The research says: don't. Estradiol protects a man's bones, heart, brain, and libido — and crashing it causes real harm.
The Theory
Block "High E2"
Testosterone → estradiol via aromatase. Clinics use low-dose anastrozole to blunt that, aiming to stop estrogen side effects like gynecomastia (breast tissue) and bloating on TRT.
The Reality: Crashed E2
Backfires
Push estradiol too low (under ~10–20 pg/mL) and men get the very things they wanted to avoid: zero libido, erectile dysfunction, crushing fatigue, joint pain, mood swings, and bone loss. Low estrogen, not high, is often the culprit.
What a Trial Showed
No Metabolic Win
An NIH randomized trial in older men with low T compared anastrozole, testosterone gel, and placebo for a year. Anastrozole raised testosterone but produced no clear metabolic benefit over placebo — not the upgrade it's marketed as.
The Bone & Sugar Cost
Real Harm
In men, estradiol is the main hormone protecting bone — suppress it long-term and bone density falls. Aromatase inhibition has also been shown to reduce insulin sensitivity in healthy men. Not a free lever to pull.
All three are old, off-patent generics — cheap by US drug standards. Letrozole in particular is nearly free with a discount card. Price is rarely the deciding factor here; the right drug for the use is.
Cheapest
Letrozole (Femara)
$0–10
per month, generic w/ discount
The fertility first-line & a top breast-cancer choice
Anastrozole (Arimidex)
~$23
per month, generic (as low as ~$9)
Breast cancer + the off-label TRT choice
Exemestane (Aromasin)
~$37
per month, generic
Steroidal type; mainly breast cancer
Compare
Clomiphene (the alternative)
~$20–50
per month, generic
Old fertility standard; letrozole now beats it
Approved narrowly, used broadly, and banned in sport. Off-label prescribing is legal and common — a doctor may prescribe an approved drug for an unapproved use — but it means the safety/dosing data for fertility and men's use is thinner than the breast-cancer label implies.
FDA
Approved only for postmenopausal breast cancer
Anastrozole, letrozole, and exemestane are FDA-approved for hormone-receptor-positive breast cancer in postmenopausal women. Fertility use, male infertility, and TRT estrogen control are all off-label — legal, but not FDA-reviewed for those uses.
WADA / USADA
Banned at all times in sport
All aromatase inhibitors are on the WADA Prohibited List (class S4, "Hormone & Metabolic Modulators") — prohibited in and out of competition. Athletes test positive for anastrozole, letrozole, and exemestane; two more AIs were added for 2026.
Pregnancy
Conceive with it, never carry on it
Letrozole for fertility is given before pregnancy and clears the body quickly. It is not to be taken once pregnant. Reassuringly, the 2023 PCOS guideline found no increased birth-defect risk vs other ovulation drugs.
The named, credentialed specialists who actually drive each use — set against what the controlled research shows. Here, refreshingly, the leading doctors and the data mostly agree.
Richard Legro, MD
Reproductive Endocrinologist · Penn State
Led the NIH "PPCOS II" trial that put letrozole on the map for fertility — showing more live births than clomiphene in women with PCOS. His work is the reason letrozole is now first-line.
vs PubMed: Agrees — the Cochrane review (41 trials) confirms letrozole's live-birth advantage at high certainty.
Mohit Khera, MD, MBA, MPH
Urologist · Men's Sexual Health · Baylor
A leading TRT authority who pushes back on the reflexive "anastrozole with every testosterone script." His message: estradiol is essential for men — don't crash it chasing a lab number.
vs PubMed: Agrees — the NIH anastrozole-in-older-men trial found no clear benefit, and suppressing estradiol harms male bone + insulin sensitivity.
Jack Cuzick, PhD
Cancer Epidemiologist · Queen Mary, London
Ran the foundational anastrozole breast-cancer trials (ATAC, IBIS-II). Established AIs as better than tamoxifen for postmenopausal HR+ disease — and flagged the bone trade-off honestly.
vs PubMed: Agrees — the EBCTCG meta-analysis confirms both the recurrence benefit and the higher fracture rate.
These are not harmless supplements. Lowering estrogen has real consequences — in both women and men. The effects below are well-documented, and they're the reason AIs should be used for a clear reason, at the lowest effective dose, with monitoring.
Bone Loss & Fractures
Estrogen protects bone — in both sexes. In the breast-cancer meta-analysis, AIs caused
27% more fractures than tamoxifen (
PMID 35123662). In men, suppressing estradiol long-term lowers bone density. Anyone on AIs long-term needs bone monitoring.
Joint Pain (Arthralgia)
The most common reason women stop AIs — aching, stiff joints affect a large share of users. In men with crashed estradiol it shows up as the same all-over joint pain. Often improves on a lower dose or a switch of drug.
Men: Crashed Estradiol
Drive E2 too low and you get the opposite of what you wanted: no libido, erectile dysfunction, fatigue, low mood, joint pain, dry skin. "More AI" is usually the wrong answer to feeling bad on TRT.
Other Effects
Hot flashes, vaginal dryness (women), raised cholesterol and reduced insulin sensitivity, fatigue, headaches. Letrozole for fertility is short-course, so its side effects are milder and brief.
Who should be careful / avoid: anyone with osteoporosis or high fracture risk (bone protection or a different drug may be needed); premenopausal women are not candidates for AIs as breast-cancer treatment unless their ovaries are also suppressed (AIs alone don't work and can backfire); and no man should be "crashing" his estrogen to hit a target number. Pregnancy: never take an AI while pregnant. None of this is medical advice — these are prescription drugs that belong with a prescriber and bloodwork.
The Bottom Line — In Plain English
An aromatase inhibitor does one thing — shuts down estrogen production — and that single lever is used for three very different jobs. Two are backed by strong evidence; one is popular but contested.
What it is
A pill (anastrozole, letrozole, or exemestane) that blocks the enzyme your body uses to make estrogen. All three are cheap generics.
Where it's proven
Postmenopausal breast cancer (FDA-approved, gold-standard) and PCOS ovulation, where letrozole is now the first-line fertility drug.
Where it's contested
Men's TRT estrogen control and male infertility — off-label, thin data, real risks. Helps a minority; harms those who crash their estrogen.
What the law says
Approved only for breast cancer; everything else is legal off-label prescribing. Banned for athletes in all sports (WADA).
The verdict
A powerful, useful drug with a clear right use for each person — and a real downside (bone, joints, crashed estrogen) when used without a reason.
- Breast cancer (postmenopausal): first-line standard, ~5 years, daily. The use with the most data behind it.
- Trying to conceive with PCOS: letrozole beats clomiphene on live births — ask your doctor about it by name.
- Male fertility: letrozole/anastrozole help men with a low testosterone-to-estradiol ratio — but clomiphene often works better, so it's not a default.
- On TRT: most men don't need one. Estradiol protects your bones, heart, and libido — don't crash it.
- Always: these are prescription drugs. Bone health and bloodwork matter. This page is information, not medical advice.